Delving into the Latest Updates on Riboflavin Butyrate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Riboflavin 2',3',4',5'-tetrabutyrate, Riboflavin Tetabutyrate, Riboflavin butyrate (JP17)

+ [6]

Target-

Mechanism-

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication

HypercholesterolemiaRiboflavin Deficiency

Inactive Indication-

Originator Organization

Mitsubishi Tanabe Pharma Corp.

Active Organization

Nipro ES Pharma KK

Chengdu Lier Pharmaceuticals Co., Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

JP (28 Sep 1979),

HypercholesterolemiaRiboflavin Deficiency

Regulation-

Login to view timeline

Structure

Molecular FormulaC33H44N4O10

InChIKeyMJNIWUJSIGSWKK-BBANNHEPSA-N

CAS Registry752-56-7

Corneal collagen crosslinking has been demonstrated as an effective method of reducing progression of both keratoconus and post-refractive corneal ectasia, as well as decreasing the steepness of the cornea in these pathologies.
Performing an accelerated CXL procedure with pulsed UVA light may increase the oxygenation of the cornea, which may improve the crosslinking efficacy.

Start Date30 Jul 2021

Sponsor / Collaborator-

NCT04905108 / RecruitingPhase 3

Randomized Study of Safety and Effectiveness of Corneal Collagen Crosslinking Using Two Different Riboflavin Administration Protocols

Corneal collagen crosslinking (CXL) has been demonstrated as an effective method of reducing progression of both keratoconus and corneal ectasia after surgery, as well as possibly decreasing the steepness of the cornea in these pathologies. Transepithelial crosslinking in which the epithelium is not removed has been proposed to offer a number of advantages over traditional crosslinking including an increased safety profile by reducing the risk for infection and scarring, faster visual recovery and improved patient comfort in the early postoperative healing period.

Start Date02 Jun 2021

Sponsor / Collaborator-

NCT04897503 / RecruitingPhase 3

Randomized Study of Safety and Effectiveness of Corneal Collagen Crosslinking Using Riboflavin/Dextran or Riboflavin/Methylcellulose

This study is being conducted to evaluate the safety and efficacy of isotonic riboflavin for corneal collagen crosslinking for keratoconus and corneal ectasia. will determine the safety and efficacy of corneal collagen crosslinking (CXL) performed with two different riboflavin formulations for reducing corneal curvature.

Start Date16 Apr 2021

Sponsor / Collaborator-

100 Clinical Results associated with Riboflavin Butyrate

Login to view more data

100 Translational Medicine associated with Riboflavin Butyrate

Login to view more data

100 Patents (Medical) associated with Riboflavin Butyrate

Login to view more data

234

Literatures (Medical) associated with Riboflavin Butyrate

01 Jan 2024·Current Research in Food Science

Impact of butyric acid modification on the structural and functional properties of rice starch

Article

Author: Liu, Xiaofei ; Wang, Bing ; Zhang, Guang ; Zhang, Na ; Wang, Yan ; Bian, Xin ; Wu, Qiaoyan ; Yang, Yang ; Ma, Chunmin ; Xu, Yue

Rice is a food with a high starch content, comprising over 75% of its composition. However, prolonged and excessive consumption of this cereal may lead to elevated blood glucose levels, which can increase the risk of obesity, type 2 diabetes, and cardiovascular disease. Butyric acid (BA), the primary energy source for colonic epithelial cells, exhibits the highest utilization rate among short-chain fatty acids, underscoring its importance for human health. In this study, rice starch butyrate (RSB) samples were synthesized using the aqueous phase process, with broken rice starch (RS) and butyric anhydride serving as the substrate. RSB samples with different degrees of substitution (DS) were produced by modulating the addition amount of butyric anhydride. The crystal structures, morphology of starch granules, pasting properties, thermal stability, and in vitro digestibilities of the RSB were investigated and compared with those of native rice starch. Fourier transform infrared (FTIR) spectroscopy confirmed the successful incorporation of butyryl into the starch molecules. With the increase in DS, the roughness of the RSB material's surface gradually increased, leading to the deterioration of the smooth structure on certain surfaces, which resulted in the appearance of cracks and collapses. Additionally, the crystallinity diminished from 24.77% to 7.41% with increasing DS. Concurrently, in vitro digestive characterisation revealed that the percentage of resistant starch increased from 24.33% to 47.72%. Thus, this study can provide a theoretical basis for the development of novel products of amyl butyrate.

04 Jul 2022·British Poultry ScienceQ3 · AGRICULTURAL & FORESTRY SCIENCE

Effects of encapsulated butyrate and salinomycin on gut leakage and intestinal inflammation in broilers

Q3 · AGRICULTURAL & FORESTRY SCIENCE

Article

Author: Naghizadeh, M. ; Klaver, L. ; Engberg, R. M. ; Dalgaard, T. S.

1. The objectives of this study were to i) compare the effects of a commercial product providing encapsulated butyrate (EB) in combination with salinomycin in diets of broilers with impaired intestinal integrity and ii) to identify easy-to-measure biomarkers to evaluate intestinal integrity and health.2. In total, 672 one-day-old male broilers (Ross 308) were randomly assigned to three experimental groups (eight replicates/group): no dietary supplement (control); EB (500 mg/kg, UltraGuard™-DUO, Devenish, Ireland); salinomycin (69 mg/kg feed, Sacox® 120). Impaired gut integrity was induced by a 10 times overdose of a commercially attenuated live vaccine against coccidiosis (Hipracox®, Hipra) on d 17 combined with a grower feed providing rye (50 g/kg diet).3. Improved intestinal integrity and functionality were reflected by reduced fluorescein isothiocyanate-dextran (FITC-D) plasma levels, reduced bacterial translocation to the liver (on d 21) and increased plasma colouration level on d 21 after dietary supplementation of salinomycin, compared to a non-supplemented control diet. Both EB and salinomycin reduced plasma levels of D-lactate (P < 0.05).4. An anti-inflammatory effect of salinomycin was indicated as the transient increase in circulating monocytes observed in the EB and control group from 20 to 28 d of age was slightly but not significantly reduced, in the salinomycin-fed group. Interestingly, greater expression of tumour necrosis factor α (TNF-α) and mucin 2 (MUC2) genes (P = 0.039 and P = 0.067, respectively) were detected in the group receiving salinomycin.5. These effects may have collectively contributed to the significantly improved performance of broilers supplemented with salinomycin. The results indicated that EB at 500 mg/kg in feed, in contrast to salinomycin, neither supported gut health nor modulated intestinal integrity in broilers.

20 Aug 2021·Science AdvancesQ1 · CROSS-FIELD

Magnetic-actuated “capillary container” for versatile three-dimensional fluid interface manipulation

Q1 · CROSS-FIELD

ArticleOA

Author: Guo, Qiuquan ; Zhang, Dongxing ; Zhang, Yiyuan ; Cai, Zheren ; Ye, Yuqing ; Qin, Feifei ; Huang, Zhandong ; Xiao, Junfeng ; Song, Yanlin ; Yang, Jun ; Li, Zheng

A previously unexplored approach enables versatile 3D fluid interface manipulation using magnetic-actuated “capillary container.”

100 Deals associated with Riboflavin Butyrate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D01913	-	S01XA26	DB14727

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Hypercholesterolemia	JP	Nipro ES Pharma KK	28 Sep 1979
Riboflavin Deficiency	JP	Nipro ES Pharma KK	28 Sep 1979

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00674661 (CXL, CTgov)	Phase 3	Corneal ectasia	130	UVA Irradiation+riboflavin ophthalmic solution (Corneal Collagen Cross-linking (CXL) Treatment Group)	xqknzxwddb(egynpeqhmb) = rvgspwmswg knxlvfaqvx (wauciyaebp, oydyqomuhr - ulzevldspm) View more	-	27 Jan 2017
				riboflavin ophthalmic solution (Control Group)	xqknzxwddb(egynpeqhmb) = zncizrmwzu knxlvfaqvx (wauciyaebp, hyqvfuphfp - ldyofawjmn) View more
NCT00647699 (CXL, CTgov)	Phase 3	Keratoconus	147	UVA Irradiation+riboflavin ophthalmic solution (Corneal Collagen Cross-linking (CXL) Treatment Group)	aottnpykdm(ucmzbfmykv) = dnglzrrtnz aqeemgrosf (kxefwdilwy, xbpbwmpjny - iqxigqthwa) View more	-	07 Jul 2016
				riboflavin ophthalmic solution (Control Group)	aottnpykdm(ucmzbfmykv) = xdtfgvedyp aqeemgrosf (kxefwdilwy, nuovspilvc - igskeynknf) View more
ISRCTN23620802 (Pubmed \| Curr Hypertens Rep)	Not Applicable	Hypertension	91	Riboflavin	(elmxyikrap) = ritrijcwmi avzguqhfrw (nrglbpxovb )	Positive	01 Jun 2013
				Placebo	(elmxyikrap) = pqkfjvidhk avzguqhfrw (nrglbpxovb )
NCT01190306 (CTgov)	Phase 3	Keratoconus	127	The VEGA UV-A Illumination System+Riboflavin (CXL Treatment)	rynrdxapdo(pxzhjlejgh) = xkdxifnyvc zgdovonjjd (unficivlmt, lytnyibvhp - qgbegqcitf) View more	-	04 Mar 2013
				Riboflavin (Sham Control)	rynrdxapdo(pxzhjlejgh) = ntkkjtwpxh zgdovonjjd (unficivlmt, kxhwkihyee - rmpvbxhqha) View more
NCT01398839 (CTgov)	Phase 3	-	103	VEGA UV-A Illumination System+Riboflavin (CXL Treatment)	xndnfakiiy(dxeoubxpgh) = ervpcjugkx yknkwzuvsn (hnigkuvaid, hiskfjohiu - ebpyvvzqgk) View more	-	04 Mar 2013
				Riboflavin (Sham Control)	xndnfakiiy(dxeoubxpgh) = iqmfzhfzfz yknkwzuvsn (hnigkuvaid, lsizflxzre - upstscngot) View more
NCT05516004 \| NCT00841386 \| NCT01325298 (Pubmed \| J Cataract Refract Surg)	Not Applicable	Keratoconus	10	Riboflavin-ultraviolet type A rays induced cross-linking of corneal collagen	xltxjqsagg(wnnsatjuoo) = ckcnfoelkz lyrwqylqfb (qrpxlzhfvu ) View more	-	01 May 2006